Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.6K
Overview
44.6K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

959
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
959
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

800
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
800
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

2.7K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.7K
Cancer Vaccines01:30

Cancer Vaccines

384
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
384
Development of Immunocompetence01:22

Development of Immunocompetence

324
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Maternal Vaccine Study Protocol: A Victorian Cohort Study Evaluating Infant and Childhood Safety and Health and Developmental Outcomes After Vaccination Against Respiratory Viruses in Pregnancy.

Vaccines·2026
Same author

ATAGI 2024 Annual Statement on Immunisation.

Communicable diseases intelligence (2018)·2026
Same author

ATAGI 2025 Annual Statement on Immunisation.

Communicable diseases intelligence (2018)·2026
Same author

ATAGI Targeted Review 2024: Immunisation strategies for prevention and control of respiratory syncytial virus disease in Australia.

Communicable diseases intelligence (2018)·2026
Same author

Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study.

Vaccine·2026
Same author

SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.

Vaccine·2026
Same journal

Measles epidemiology in Australia: 2014 to 2024. Erratum to 10.33321/cdi.2026.50.016.

Communicable diseases intelligence (2018)·2026
Same journal

Presymptomatic transmission, vaccine breakthrough and anonymous contacts: a cluster of mpox in Canberra, Australian Capital Territory, 2024.

Communicable diseases intelligence (2018)·2026
Same journal

The Strategic Plan for Tuberculosis Elimination and Equity in Australia 2026-2030.

Communicable diseases intelligence (2018)·2026
Same journal

An atlas of common Salmonella serotypes from routinely notified human cases in the Northern Territory of Australia, 2005-2024.

Communicable diseases intelligence (2018)·2026
Same journal

Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2025.

Communicable diseases intelligence (2018)·2026
Same journal

Australian Gonococcal Surveillance Program, 1 October to 31 December 2025.

Communicable diseases intelligence (2018)·2026
See all related articles

Related Experiment Video

Updated: Jul 14, 2025

Optimization of Antigen Preparation for Hemagglutination Inhibition Assay of Newcastle Disease Virus Serology
07:04

Optimization of Antigen Preparation for Hemagglutination Inhibition Assay of Newcastle Disease Virus Serology

Published on: January 24, 2025

442

ATAGI 2023 Annual Statement on Immunisation

Madeline Valeri1, Shireen Durrani1, Catherine Tran1

  • 1National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Sydney, New South Wales, Australia.

Communicable Diseases Intelligence (2018)
|October 11, 2023
PubMed
Summary

No abstract available in PubMed .

More Related Videos

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

36.1K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K

Related Experiment Videos

Last Updated: Jul 14, 2025

Optimization of Antigen Preparation for Hemagglutination Inhibition Assay of Newcastle Disease Virus Serology
07:04

Optimization of Antigen Preparation for Hemagglutination Inhibition Assay of Newcastle Disease Virus Serology

Published on: January 24, 2025

442
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

36.1K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K